Glaukos Co. (NYSE:GKOS) Shares Sold by Park Place Capital Corp

Park Place Capital Corp reduced its stake in shares of Glaukos Co. (NYSE:GKOS) by 21.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 237 shares of the medical instruments supplier’s stock after selling 65 shares during the period. Park Place Capital Corp’s holdings in Glaukos were worth $36,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Values First Advisors Inc. purchased a new stake in shares of Glaukos during the 3rd quarter valued at approximately $25,000. Harvest Fund Management Co. Ltd raised its position in shares of Glaukos by 2,263.2% during the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock valued at $117,000 after buying an additional 860 shares during the period. KBC Group NV raised its position in shares of Glaukos by 16.2% during the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock valued at $188,000 after buying an additional 201 shares during the period. EWA LLC purchased a new stake in shares of Glaukos during the 3rd quarter valued at approximately $209,000. Finally, Procyon Advisors LLC purchased a new stake in shares of Glaukos during the 3rd quarter valued at approximately $210,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Glaukos Stock Up 0.9 %

Glaukos stock opened at $161.55 on Friday. Glaukos Co. has a twelve month low of $83.90 and a twelve month high of $163.71. The stock’s fifty day simple moving average is $146.86 and its 200-day simple moving average is $134.31. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $8.91 billion, a P/E ratio of -53.49 and a beta of 1.04.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.20. The business had revenue of $96.70 million for the quarter, compared to analyst estimates of $91.50 million. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The company’s revenue was up 23.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.50) earnings per share. As a group, equities analysts expect that Glaukos Co. will post -1.89 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Gilbert H. Kliman sold 10,000 shares of the business’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $150.28, for a total transaction of $1,502,800.00. Following the completion of the transaction, the director now owns 32,336 shares in the company, valued at approximately $4,859,454.08. The trade was a 23.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Joseph E. Gilliam sold 2,275 shares of the company’s stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total transaction of $316,156.75. Following the completion of the transaction, the chief operating officer now owns 102,169 shares of the company’s stock, valued at $14,198,425.93. This represents a 2.18 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 17,603 shares of company stock worth $2,605,678. Corporate insiders own 6.40% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on GKOS. StockNews.com raised shares of Glaukos from a “sell” rating to a “hold” rating in a research report on Monday, October 21st. Morgan Stanley lowered shares of Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price target on the stock. in a research report on Monday, December 2nd. Stifel Nicolaus boosted their target price on Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a research report on Tuesday, December 31st. Citigroup raised Glaukos from a “neutral” rating to a “buy” rating and boosted their target price for the company from $132.00 to $162.00 in a research report on Wednesday, December 11th. Finally, Wells Fargo & Company boosted their target price on Glaukos from $145.00 to $153.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $147.75.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.